TY  - JOUR

T1  - Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

JO  - BJU International

UR  - http://eprints.whiterose.ac.uk/104430/

PY  - 2016/06/03

AU  - Andronis L

AU  - Goranitis I

AU  - Pirrie S

AU  - Pope A

AU  - Barton D

AU  - Collins S

AU  - Daunton A

AU  - McLaren D

AU  - O'Sullivan JM

AU  - Parker C

AU  - Porfiri E et al

ED  - 

DO  - DOI: 10.1111/bju.13549

Y2  - 2024/12/22

ER  -